NovaBay Capex To Revenue vs Total Revenue Analysis

NBY Stock

USD 0.60 0.01 1.69%

NovaBay Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NovaBay Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NovaBay Pharmaceuticals is a good investment. Please check the relationship between NovaBay Pharmaceuticals Capex To Revenue and its Total Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Capex To Revenue vs Total Revenue

Capex To Revenue vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NovaBay Pharmaceuticals Capex To Revenue account and Total Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between NovaBay Pharmaceuticals' Capex To Revenue and Total Revenue is -0.58. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of NovaBay Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NovaBay Pharmaceuticals' Capex To Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of NovaBay Pharmaceuticals are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Capex To Revenue i.e., NovaBay Pharmaceuticals' Capex To Revenue and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.58

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Total Revenue

Total revenue comprises all receipts NovaBay Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from NovaBay Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Selling General Administrative is likely to rise to about 7.5 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	5.6M	7.8M	7.9M	8.1M
Total Revenue	8.4M	14.4M	14.7M	10.0M

Gross Profit Total Revenue

NovaBay Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Liab	Current Deferred Revenue	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt
Total Assets		0.83	-0.37	-0.19	0.33	0.45	0.15	0.17	0.33	-0.61	-0.25	-0.16	0.73	0.64	0.63	0.5	0.6	0.37	0.87	0.59	0.3	0.23	-0.11	0.12	-0.19	0.0
Total Stockholder Equity	0.83		-0.11	-0.34	0.15	-0.11	0.0	-0.2	0.28	-0.76	-0.04	-0.4	0.79	0.34	0.74	0.54	0.53	0.29	0.88	0.62	0.33	0.2	0.06	-0.21	-0.29	-0.18
Other Assets	-0.37	-0.11		0.08	0.06	-0.49	-0.44	-0.45	-0.23	0.25	-0.09	-0.56	-0.31	-0.02	-0.38	-0.33	-0.41	-0.15	-0.39	-0.3	-0.18	0.38	0.55	0.07	-0.07	-0.43
Common Stock Shares Outstanding	-0.19	-0.34	0.08		0.28	0.22	0.09	0.62	-0.06	0.3	-0.26	-0.32	-0.25	-0.17	-0.31	-0.33	-0.53	-0.14	-0.16	-0.3	-0.41	-0.4	0.35	-0.16	0.88	0.07
Other Stockholder Equity	0.33	0.15	0.06	0.28		0.35	0.09	0.6	0.36	0.17	-0.9	0.05	-0.05	0.48	-0.25	0.39	0.23	0.52	0.07	0.26	0.26	0.47	-0.05	-0.21	0.27	0.01
Total Liab	0.45	-0.11	-0.49	0.22	0.35		0.26	0.63	0.12	0.06	-0.34	0.37	0.05	0.6	-0.03	0.05	0.23	0.2	0.16	0.1	-0.06	0.03	-0.29	0.57	0.15	0.24
Other Current Liab	0.15	0.0	-0.44	0.09	0.09	0.26		0.48	-0.27	-0.35	-0.06	0.29	0.37	-0.35	0.28	-0.1	0.1	-0.36	0.34	-0.15	-0.16	-0.28	-0.33	-0.28	0.2	0.03
Total Current Liabilities	0.17	-0.2	-0.45	0.62	0.6	0.63	0.48		0.32	0.24	-0.61	0.25	-0.06	0.09	-0.19	0.06	-0.03	0.29	0.06	0.0	0.08	-0.08	-0.18	-0.19	0.65	0.36
Property Plant And Equipment Net	0.33	0.28	-0.23	-0.06	0.36	0.12	-0.27	0.32		0.14	-0.37	-0.04	0.1	0.27	0.13	0.45	0.09	0.95	0.21	0.38	0.75	0.44	-0.17	-0.19	0.02	0.55
Net Debt	-0.61	-0.76	0.25	0.3	0.17	0.06	-0.35	0.24	0.14		-0.39	0.22	-0.91	0.0	-0.93	-0.35	-0.43	0.21	-0.86	-0.49	0.19	0.27	0.16	0.08	0.24	0.17
Retained Earnings	-0.25	-0.04	-0.09	-0.26	-0.9	-0.34	-0.06	-0.61	-0.37	-0.39		-0.06	0.16	-0.43	0.42	-0.29	-0.18	-0.51	0.06	-0.08	-0.42	-0.63	0.05	0.21	-0.22	-0.13
Accounts Payable	-0.16	-0.4	-0.56	-0.32	0.05	0.37	0.29	0.25	-0.04	0.22	-0.06		-0.24	0.05	-0.23	0.18	0.41	0.03	-0.29	0.14	0.09	-0.04	-0.65	0.13	-0.22	0.23
Cash	0.73	0.79	-0.31	-0.25	-0.05	0.05	0.37	-0.06	0.1	-0.91	0.16	-0.24		0.05	0.92	0.45	0.43	0.0	0.91	0.49	0.01	-0.04	-0.32	-0.13	-0.25	0.13
Non Current Assets Total	0.64	0.34	-0.02	-0.17	0.48	0.6	-0.35	0.09	0.27	0.0	-0.43	0.05	0.05		-0.03	0.34	0.48	0.49	0.21	0.46	0.23	0.49	0.02	0.57	-0.29	-0.11
Cash And Short Term Investments	0.63	0.74	-0.38	-0.31	-0.25	-0.03	0.28	-0.19	0.13	-0.93	0.42	-0.23	0.92	-0.03		0.37	0.33	0.0	0.89	0.45	-0.01	-0.22	-0.27	-0.08	-0.25	0.11
Common Stock Total Equity	0.5	0.54	-0.33	-0.33	0.39	0.05	-0.1	0.06	0.45	-0.35	-0.29	0.18	0.45	0.34	0.37		0.78	0.52	0.42	0.76	0.42	0.33	-0.48	-0.25	-0.3	0.33
Other Current Assets	0.6	0.53	-0.41	-0.53	0.23	0.23	0.1	-0.03	0.09	-0.43	-0.18	0.41	0.43	0.48	0.33	0.78		0.2	0.45	0.75	0.3	0.24	-0.41	0.0	-0.49	-0.04
Property Plant And Equipment Gross	0.37	0.29	-0.15	-0.14	0.52	0.2	-0.36	0.29	0.95	0.21	-0.51	0.03	0.0	0.49	0.0	0.52	0.2		0.15	0.4	0.78	0.59	-0.12	-0.07	-0.05	0.41
Total Current Assets	0.87	0.88	-0.39	-0.16	0.07	0.16	0.34	0.06	0.21	-0.86	0.06	-0.29	0.91	0.21	0.89	0.42	0.45	0.15		0.51	0.15	-0.07	-0.1	-0.14	-0.08	-0.02
Common Stock	0.59	0.62	-0.3	-0.3	0.26	0.1	-0.15	0.0	0.38	-0.49	-0.08	0.14	0.49	0.46	0.45	0.76	0.75	0.4	0.51		0.19	0.09	-0.28	-0.08	-0.31	0.05
Property Plant Equipment	0.3	0.33	-0.18	-0.41	0.26	-0.06	-0.16	0.08	0.75	0.19	-0.42	0.09	0.01	0.23	-0.01	0.42	0.3	0.78	0.15	0.19		0.64	-0.08	-0.28	-0.22	0.26
Other Liab	0.23	0.2	0.38	-0.4	0.47	0.03	-0.28	-0.08	0.44	0.27	-0.63	-0.04	-0.04	0.49	-0.22	0.33	0.24	0.59	-0.07	0.09	0.64		-0.11	0.09	-0.46	0.14
Current Deferred Revenue	-0.11	0.06	0.55	0.35	-0.05	-0.29	-0.33	-0.18	-0.17	0.16	0.05	-0.65	-0.32	0.02	-0.27	-0.48	-0.41	-0.12	-0.1	-0.28	-0.08	-0.11		-0.01	0.41	-0.69
Non Current Liabilities Total	0.12	-0.21	0.07	-0.16	-0.21	0.57	-0.28	-0.19	-0.19	0.08	0.21	0.13	-0.13	0.57	-0.08	-0.25	0.0	-0.07	-0.14	-0.08	-0.28	0.09	-0.01		-0.3	-0.06
Short Long Term Debt Total	-0.19	-0.29	-0.07	0.88	0.27	0.15	0.2	0.65	0.02	0.24	-0.22	-0.22	-0.25	-0.29	-0.25	-0.3	-0.49	-0.05	-0.08	-0.31	-0.22	-0.46	0.41	-0.3		-0.03
Short Term Debt	0.0	-0.18	-0.43	0.07	0.01	0.24	0.03	0.36	0.55	0.17	-0.13	0.23	0.13	-0.11	0.11	0.33	-0.04	0.41	-0.02	0.05	0.26	0.14	-0.69	-0.06	-0.03

Click cells to compare fundamentals

NovaBay Pharmaceuticals Account Relationship Matchups

NovaBay Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.2M	15.2M	24.0M	16.4M	9.0M	14.4M
Total Stockholder Equity	973K	12.3M	10.2M	10.6M	3.3M	5.3M
Other Assets	477K	912K	476K	489K	562.4K	461.6K
Common Stock Shares Outstanding	618.3K	28.6K	35.6K	46K	120.4K	125.5K
Liabilities And Stockholders Equity	11.2M	15.2M	24.0M	16.4M	9.0M	14.4M
Other Stockholder Equity	125.7M	148.0M	150.9M	165.1M	176.1M	88.1M
Total Liab	10.2M	2.9M	13.8M	5.8M	5.7M	7.1M
Other Current Liab	993K	1.7M	763K	667K	1.0M	1.3M
Total Current Liabilities	5.7M	2.8M	3.4M	4.3M	4.3M	4.1M
Property Plant And Equipment Net	1.4M	520K	604K	2.0M	1.4M	1.0M
Net Debt	(2.9M)	(11.4M)	(7.0M)	(3.3M)	(390K)	(409.5K)
Retained Earnings	(125.0M)	(136.1M)	(141.9M)	(158.2M)	(174.8M)	(166.1M)
Accounts Payable	331K	302K	1.0M	1.1M	1.1M	812.7K
Cash	6.9M	12.0M	7.5M	5.4M	3.1M	6.0M
Non Current Assets Total	1.8M	996K	10.8M	5.1M	1.9M	2.0M
Cash And Short Term Investments	6.9M	12.0M	7.5M	5.4M	3.1M	3.0M
Common Stock Total Equity	154K	171K	279K	418K	480.7K	263.6K
Other Current Assets	105K	576K	778K	560K	388K	463.4K
Property Plant And Equipment Gross	1.4M	520K	1.2M	2.6M	2.1M	1.1M
Total Current Assets	9.4M	14.2M	13.2M	11.3M	7.2M	9.5M
Accumulated Other Comprehensive Income	(243K)	(509K)	(560K)	(275K)	(247.5K)	(259.9K)
Common Stock	279K	418K	478K	652K	112K	106.4K
Property Plant Equipment	110K	520K	604K	2.0M	1.8M	1.8M
Other Liab	2.5M	560K	4.1M	10.1M	11.6M	12.2M
Current Deferred Revenue	822K	730K	1.3M	1.8M	946K	1.2M
Non Current Liabilities Total	4.6M	87K	10.4M	1.6M	1.4M	2.6M
Short Term Debt	3.5M	832K	505K	906K	2.1M	2.2M
Non Currrent Assets Other	77K	2K	476K	489K	497K	300.0K
Net Receivables	1.1M	1.1M	1.7M	2.0M	759K	721.1K
Net Tangible Assets	5.0M	973K	12.3M	(237K)	(213.3K)	(202.6K)
Retained Earnings Total Equity	(111.1M)	(115.0M)	(125.0M)	(136.1M)	(122.5M)	(116.3M)
Capital Surpluse	125.7M	148.0M	150.9M	165.1M	189.8M	118.8M
Inventory	492K	608K	3.2M	3.4M	2.9M	3.0M
Non Current Liabilities Other	198K	4.6M	561K	334K	300.6K	285.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NovaBay Capex To Revenue vs Total Revenue Analysis

Capex To Revenue vs Total Revenue

Capex To Revenue vs Total Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Total Revenue

NovaBay Pharmaceuticals fundamental ratios Correlations

NovaBay Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NovaBay Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for NovaBay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 0.95	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.92	Cash
Total Current Assets	+ 0.91	Cash
Total Current Assets	+ 0.89	Cash And Short Term Investments
Total Current Assets	+ 0.88	Total Stockholder Equity
Short Long Term Debt Total	+ 0.88	Common Stock Shares Outstanding

Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.91	Net Debt
Retained Earnings	- 0.9	Other Stockholder Equity
Total Current Assets	- 0.86	Net Debt
Net Debt	- 0.76	Total Stockholder Equity
Short Term Debt	- 0.69	Current Deferred Revenue